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INTRODUCTION
Head and neck cancer is the fifth most common cancer world-
wide, accounting for over 35,000 new cases of cancer each year 
in the United States alone (1). Despite technical advances in 
surgery, radiotherapy, and chemotherapy, survival rates have re-
mained virtually unchanged over the last 50 years (2). Recently, 
the primary treatment modalities have increasingly shifted from 
surgery to chemotherapy and/or radiotherapy (3). A number of 
anti-tumor agents for chemotherapy have been developed and 
used; however, the considerable toxic effects of the current drug 
therapies have decreased the quality of life of the patients treat-
ed with these agents (4). The limitations of current therapy have 
motivated the investigation and evaluation of novel bioactive 
compounds, especially from natural products (5).
Objectives. To determine whether a novel marine micro-organism with anticancer properties, H31, the metabolic product 
of Bacillus SW31, has anti-tumor effects on head and neck cancer, and potential for apoptotic-enhancing anti-cancer 
treatment of affected patients.
Methods. The cell viability and apoptosis assays were performed. Changes in the signal pathway related to apoptosis were 
investigated. Then, the therapeutic effects of H31 were explored in mouse xenograft model and drug toxicity of H31 
was examined in zebrafish model. 
Results. We identified the anticancer activity of H31, a novel metabolic product of Bacillus SW31. Bacillus SW31, a new 
marine micro-organism, has 70% homology with Bacillus firmus and contains potent cytotoxic bioactivity in head 
and neck cancer cells using MTT assay. Combined with c-JUN, p53, cytochrome C, and caspase-3, H31 induced 
apoptosis of KB cells, a head and neck cancer cell line. In a separate in vivo model, tumor growth in C3H/HeJ synge-
neic mice was suppressed by H31. In addition, in a zebrafish model used for toxicity testing, a considerable dose of 
H31 did not result in embryo or neurotoxicity. 
Conclusion. Growth inhibition and apoptosis were achieved both in vitro and in vivo in head and neck cancer cells after 
exposure to H31, a metabolite from the marine Bacillus species, without any significant toxicity effects even at con-
siderable H31 dose concentrations.
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  The ocean has always been a source for new bioactive metab-
olites, especially from micro-organisms (6). Over 200 novel me-
tabolites were identified from marine micro-organisms in 2005 
alone (7). Recent studies have reported that natural products 
from marine micro-organisms have potent cytotoxic characteris-
tics, potentially useful for future pharmaceutical and biomedical 
applications (8). 
  One key mechanism associated with cancer cell growth is the 
control of apoptosis. Apoptosis is defined as programmed cell 
death, which occurs in response to disruption of normal homeo-
static mechanisms; it is critical to the surveillance of tumor and/
or malfunctioning cells (9). Induction of apoptosis among cancer 
cells has been considered one potential novel approach to the 
treatment of head and neck cancer (10).
  Therefore, the goal of this study was to determine whether a 
novel marine micro-organism with anticancer properties, H31, 
the metabolic product of Bacillus SW31, has anti-tumor effects 
on head and neck cancer, and potential for apoptotic-enhancing 
anti-cancer treatment of affected patients.
MATERIALS AND METHODS
Isolation and identification of cytotoxic Bacillus SW31
Seawater samples were collected from Kanghwa Island (western 
coast of Korea). The seawater samples (0.1 mL) were streaked 
onto the surface of 1/10 marine agar (bacto tryptone 5 g, yeast 
extract 3 g, bacto agar 10 g, glycerol 3 mL, dissolved in 75% 
seawater, pH 7.5). After incubation at room temperature for 24 
hours, all colonies were chosen for isolation. 
  Among 753 samples (from 188 strains) isolated, the individual 
strain that showed the strongest cytotoxic effects on head and 
neck cancer cells (FaDu, KB, SNU 899, SNU1066) by 3-(4,5-di-
methyl-thiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide 
(MTT) assay was selected. We then performed biochemical tests 
to analyze the physiological and metabolic characteristics to 
identify the specific bacterial strain. This strain was grown at 
25°C under aerobic conditions for 3 days in sea water complete 
medium (bacto tryptone 5 g, yeast extract 3 g, glycerol 3 mL, 
dissolved in 75% seawater, pH 7.5). Extraction of genomic 
DNA and 16S rRNA gene amplification were carried out ac-
cording to the method reported by Rainey et al. (11). The result-
ing polymerase chain reaction (PCR) product was ligated into a 
pGEM-T easy vector (Promega, Madison, WI, USA), sequenced 
using a Termination Sequencing Ready Reaction kit (Perkin El-
mer, Boston, MA, USA), and analyzed using an ABI 377 genetic 
analyzer (Perkin Elmer). The complete 16S rDNA sequence 
(1,485 bp) was aligned using the CLUSTAL W software pro-
gram (12). The 16S rDNA sequences used for the phylogenetic 
analyses were derived and compared with those of other bacte-
rial 16S rDNA sequences available in the DDBJ⁄EMBL⁄GenBank 
database. Kimura’s two-parameter model was used for the cal-
culation of evolutionary distance (13). Our 16S rDNA sequenc-
ing of the strain characterized it to be most similar to Bacillus 
firmus (71.1% homology). We named the new marine strain 
Bacillus SW31 and added it to the Korean Collection of Type 
Cultures under accession number KCTC 11135BP. Table 1 
shows the results of the biochemical tests of Bacillus SW31 us-
ing the Easy 24E Plus Kit (Komed, Seoul, Korea). 
Bacterial culture and isolation of single pure cytotoxic com-
pounds 
For the production of secondary metabolites, the Bacillus SW31 
was cultured in Erlenmeyer flasks containing sea water com-
plete medium. The flasks were then incubated on a shaker at 
150 rev min
-1 for 3 days at 25°C. The culture broth was centri-
fuged (10,000 rpm for 5 minutes at 4°C) to remove the cells, 
and then hexane 100 mL was added. The hexane was concen-
trated by a rotary vacuum evaporator and the new metabolic 
product obtained was named H31. The H31 (3 g) was further 
purified by reverse phase HPLC (Shimadzu, Tokyo, Japan; Cos-
mosil 5C18-MS column, 10×250 mm; linear gradient of MeOH 
in H2O containing 0.05% trifluoroacetic acid [TFA], 80–100% 
in 50 minutes; flow rate, 1.5 mL min
-1; UV detection at 210 nm) 
to yield a pure cytotoxic compound (PCC). 
Cell lines 
Human FaDu and KB, SNU 899, SNU1066 (head and neck 
Table 1. Biochemical characteristics of marine Bacillus SW31 
Test Substrates utilization
Bacillus 
SW31
1 ARA Arabitol -
2 LAC Lactose -
3 SUC Sucrose -
4 MAN Mannitol -
5 DUL Dulcitol -
6 ADO Adonitol -
7 SOR Sorbitol -
8 CEL Cellobiose -
9 RAF Raffinose -
10 RHA Rhamnose -
11 INO Inositol -
12 MAL Maltose -
13 G-side Glucopyranoside -
14 ESC Esculin +
15 ONPG O-Nitrophenyl-β-D-galactopyranoside -
16 IND Tryptophan -
17 PDA Phenylalanine +
18 NIT Potassiumnitrate  -
19 URE Urease +
20 H2S H2S production from Sodium thiosulfate +
21 LYS (LDC) Lysine decarboxylase -
22 ARG (ADH) Arginine dehydrogenase +
23 ORN (ODC) Ornithine decarboxylase +
24 F Glucose -Lim YC et al.: Anticancer effect of H31 Metabolites from Marine Bacillus SW31    219
cancers), AGS (gastric cancer), HepG2 (liver cancer), and HT29 
(colon cancer) were obtained from the American Type Culture 
Collection (Rockville, MD, USA) and Korean Cell Line Bank 
(Seoul, Korea). The cells were grown in Dulbecco’s modified Ea-
gle’s medium (DMEM) or RPMI 1640 medium, supplemented 
with 10% fetal bovine serum (FBS) with penicillin-streptomycin 
at 37°C in a humidified 5% CO2 atmosphere. SCC VII/SF cell 
lines were grown in RPMI 1640 medium supplemented with 
10% FBS and antibiotics.
Cell viability assay
To determine cell viability, the cells were seed in 96-well plates 
at densities of 5×10
3 cells/well in 1 mL complete medium after 
the cells were exposed to various concentrations of H31. Then, 
MTT was added to 40 µL of cell suspension for 4 hours. After 
three washes with PBS, the insoluble formazan product was dis-
solved in DMSO. The optical density (OD) of each culture well 
was measured using a microplate reader (Bio-Tek, Winooski, VT, 
USA) at 540 nm.
DNA fragmentation analysis
We performed DNA fragmentation tests with the G-DEX II Ge-
nomic DNA Extraction Kit (Intron, Seoul, Korea). Briefly, the 
cells were plated in 6-well plates at 3×10
5 cell/well, incubated 
for 24 hours, and then treated with different H31 concentrations 
for 24 hours in the absence of serum. After the cells were 
washed twice with PBS, they were harvested then lysed in 150 
µL of cell lysis buffer with 1 µL RNAase A solution for 30 min-
utes at 37°C. The cell lysates were cleared by centrifugation. Af-
ter centrifugation, the supernatant was collected and treated 
with 150 µL of 100% isopropanol by gently mixing. Centrifuge 
was performed at room temperature for 5 minutes at 13,000 
rpm. The supernatant was discarded and treated with 1 mL of 
75% EtOH by gently mixing. After centrifugation, the superna-
tant was discarded and the pellet was air dried. DNA was ob-
tained by adding precipitation solution. The DNA pellet was dis-
solved in 50 µL of TE buffer (100 mM Tris-Cl pH7.4 and 10 mM 
EDTA pH8.0) containing RNase and incubated for 1 hour at 
37°C. The fragmented DNA was resolved on 2% agarose gels in 
the presence of ethidium bromide and electrophoresed for 30 
minutes at 100 V and then the bands were detected by UV light.
Cell cycle analysis
Cells were plated at 1×10
6 cell/well in 6-well plates, incubated 
for 24 hours, and then treated with different concentrations of 
H31 for 24 hours. Trypsinized cells were washed with PBS and 
fixed in 70% ethanol. After fixation, the cells were incubated for 
30 minutes with 200 mg/mL of RNase A and stained with 5 mg/
mL propidium iodide (PI). The stained cells were analyzed using 
a flow cytometry cell sorter (Becton Dickinson, Franklin Lakes, 
NJ, USA). In addition, the cells were conjugated with Annexin 
V-FITC using a TACS Annexin V-FITC kit (Trevigen Inc., Gaith-
ersburg, MD, USA) according to the manufacturer’s protocol 
and analyzed by flow cytometry.
Terminal deoxyuncleotidyl transferase (TdT)-mediated dUTP-
biotin nick end labeling (TUNEL) assay
The apoptotic effects of H31 were also determined by the TU-
NEL method using an in situ cell detection kit (Roche Molecular 
Biochemicals, Mannheim, Germany). KB cells were glass cover-
slipped in 24-well dishes containing growth medium. After 60-
70% cell confluence was achieved, the cells were exposed to 
different H31 concentrations. The cells were incubated with 50 
µL of TUNEL reaction mixture at 37°C for 1 hour in a humid 
atmosphere. The cells were then stained with 5 µg/mL Hoechst 
33258 for 5 minutes, and the stained cells were visualized un-
der a fluorescence microscope.
Western blot analysis
The level of protein expression was evaluated using Western blot 
analysis. The KB cells were washed with PBS and isolated in 
RIPA (radioimmunoprecipitation) buffer. The mixture was cen-
trifuged at 12,000 rpm for 5 minutes at 4°C. Then, 20 µg of total 
proteins per well were separated by SDS-PAGE, and were trans-
ferred to a nitrocellulose membrane (Amersham, Arlington 
Heights, IL, USA). The membrane was incubated with specific 
antibodies overnight at 4°C. The membrane was reacted with 
peroxidase-conjugated donkey anti-rabbit antibodies (Amer-
sham, Piscataway, NJ, USA) or donkey anti-mouse antibodies 
(Amersham, Piscataway). The membrane was developed using 
the Enhanced Chemiluminescence (ECL) Detection System 
(Amersham, Piscataway) and X-ray film. 
In vivo syngeneic mouse C3H/HeJ model
The animal experiments were approved by the Animal Care and 
Use Committee of Ajou University. For the in vivo study, we 
used a syngeneic mouse model (C3H/HeJ mice, SCC VII/SF 
cell) that is commonly used for an in vivo immunocompetent 
murine model of head and neck cancer (14, 15). Six-week-old 
female C3H/HeJ syngeneic mice (about 20 g weight) were ob-
tained from Orient (Orient Bio, Seoul Korea) and were accli-
mated in pathogen-free conditions for 1 week. All mice were 
then injected subcutaneously with 5×10
5 viable SCC VII/SF 
cells into the right flank. Three mice were given daily intraperi-
toneal injections of distilled water (D.W, control group), and the 
other three mice received intraperitoneal injections of 0.2 mg 
H31 (treatment group) 5 days a week. The tumor size, in two 
perpendicular diameters, was measured with calipers every sec-
ond day. The tumor volume was calculated by the formula V= 
(π/6)×(L×W
2) (L: large diameter, W: smaller diameter) (16).
  Growth curves were plotted using the average tumor size 
within each experimental group at the same points in time. The 
animals were euthanized and the tumors were collected and 
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by cervical dislocation, and the tumors were excised and divided 
into two parts. For each sample, the final tumor size and weight 
were calculated.
Immunohistochemistry (IHC)
Active caspase-3 IHC was performed on paraffin-embedded 
mouse squamous carcinoma tumor sections collected on polyly-
sine-coated slides. After paraffin removal, using xylene, the sec-
tions were rehydrated and incubated with 0.3% hydrogen per-
oxide for 10 minutes to eliminate endogenous peroxidase activ-
ity. The specimens were incubated with anti-active caspase-3 
mouse primary antibodies (Cell signaling Technology, Danvers, 
MA, USA) diluted 1:400 in blocking solution overnight at 4°C. 
The sections were incubated for 2 hours at room temperature 
with the streptavidin–biotin–peroxidase complex (Vectastain 
ABC kit, Vector Laboratories, Burlingame, CA, USA). The im-
munolabeling was revealed after three washes in PBS using 2,3′ 
diaminobenzidene as substrate diluted 1:10 in buffer according 
to the manufacturer’s instructions (Roche Molecular Biochemi-
cals, Mannheim, Germany). Staining was performed by incuba-
tion with the 3,3-diaminobenzidine (DAB) substrate-chromo-
gen, which results in a brown-colored precipitate at the antigen 
site. Measurements of active caspase-3-positive cells were per-
formed on 10–15 images/slide identified by an independent ob-
server blinded to the experiment and normalized to the total 
cell count by DAPI staining. A minimum of five sections were 
randomly selected for the analysis of the apoptotic index, and 
the number of apoptotic cells were viewed under the light mi-
croscope (Leica, Wetzlar, Germany). 
Embryotoxicity and neurotoxicity evaluation in vivo using a
zebrafish model
Wild-type zebrafish (Danio rerio) was maintained at 28.5°C on 
a 14 hours light/10 hours dark cycle. For the embryotoxicity 
evaluation, fertilized eggs were exposed to various concentra-
tions of H31 or 100 µM cisplatin diluted with Danieu’s Solution, 
and maintained in an incubator at 28.5°C for 1 hour. After H31 
treatment, evaluation for egg death, organogenesis, hatch rate, 
and any abnormal features was performed. For the neurotoxici-
ty evaluation, 4 days post fertilization (dpf) larvae were placed 
at a density of 50 per 100 mm
2 in a petri dish with embryo me-
dium (1 mM MgSO4, 120 µM KH2PO4, 74 µM NaHPO4, 1 mM 
CaCl2, 500 µM KCl, 15 µM NaCl, and 500 µM NaHCO3) and 
placed in an incubator at 28.5°C. Then, 4 dpf zebrafish larvae 
were exposed to different concentrations of H31 diluted with 
Danieu’s Solution, and maintained in an incubator at 28.5°C for 
1 hour. After the larvae were washed with 0.3×Danieu’s Solu-
tion and cultured at 28.5°C for 3 hours, and labeled using 2 µM 
YO-PRO1 (Molecular Probes, Eugene, OR, USA) for 1 hour, 
performed three times. The zebrafish was then anesthetized with 
8 µg/mL 3-aminobenzoic acid ethyl ester methanesulfonate salt 
(MS222, Sigma Chemical Co., St Louis, IL, USA). After fixation, 
the zebrafish was mounted with methylcellulose on a slide and 
photographs were taken using a fluorescence microscope. 
Statistical analysis 
The Student t-test and one-way ANOVA were used for the sta-
tistical analyses with SPSS ver. 10.0 (SPSS Inc., Chicago, IL, 
USA). Statistical significance was defined at P<0.05. 
RESULTS
H31 inhibited cell growth in head and neck cancer cells 
Our primary aim was to investigate whether H31 had strong cy-
totoxic activity in four head and neck cancer cell lines. As 
shown in Fig. 1, the MTT assay shows that the cell viability 
dropped by 40% or more when the cells were treated with 10 
µg/mL of H31, among all four cell lines. The antitumor activity 
of H31 was strongest in the FaDu cells and KB cells among the 
four cell lines; therefore KB cells were used for further experi-
ments.
H31 induced apoptosis of KB cells 
To investigate the mechanism of H31-induced growth inhibition 
of KB cells, we studied internucleosomal DNA cleavage by 
DNA fragmentation analysis for the detection of apoptosis. 
DNA fragmentation was observed at 24 hours after H31 treat-
ment, a characteristic feature of apoptosis, which was not noted 
in the ethanol-treated control group (Fig. 2A). The TUNEL assay 
also showed that H31 increased the unclear condensation, DNA 
fragmentation, and perinuclear apoptotic bodies in the KB cells 
Fig. 1. Four head and neck cancer cell lines (FaDu, SNU 899, SNU
1066, and KB) were incubated with different concentrations (1, 10, 
100 µg/mL) of H31 for 24 hours, and cell viability was evaluated by 
the MTT assay. The data represent the mean±SD of three indepen-
dent experiments; **P<0.01, ***P<0.001 by student t-test, com-
pared to medium alone.
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as detected by Hoechst 33258 staining (Fig. 2B). In addition, the 
amount of sub-G1 DNA was investigated, which contained less 
DNA than the G1 cells, to quantify the amount of apoptotic cells. 
Flow cytometric analysis showed that H31 treatment increased 
accumulation during the sub-G1 phase in a dose-dependent 
manner (Fig. 2C). Furthermore, annexin V analysis showed that 
the percentage of apoptotic cells (annexin V-positive, PI-negative, 
bottom right quadrants) increased in a dose-dependant manner 
(Fig. 2D). Therefore, H31 induced apoptosis in the KB cells
Apoptosis by H31 was associated with involvement of c-jun, 
p53, cytochrome C, and caspase-3
To study the mechanism of H31-induced apoptosis in the KB 
Fig. 2. Effect of H31 on apoptosis and the cell cycle in KB cells. (A) DNA fragmentation analysis: KB cells were grown for 24 hours at different 
concentrations of H31; a DNA fragmentation assay was performed with an ApopLadder EX DNA fragmentation assay kit. DNA fragmentation 
was visualized by electrophoresis on a 2% agarose gel containing ethidium bromide. lane 1, control; lane 2, H31 30 µg/mL; lane 3, H31 50 µg/
mL; lane 4, H31 70 µg/mL; lane 5, H31 100 µg/mL. (B) TUNEL study: apoptosis in KB cells was determined by the TUNEL method using an in 
situ cell detection kit. The cells were then incubated with 50 μL of TUNEL reaction mixture (TdT and fluoresccin–dUTP) and stained with 
Hoechst 33258 (5 µg/mL). The stained cells (arrowhead) were observed under a fluorescence microscope. Scale bar=50 µm. (C) Flow cy-
tometry: KB cells were incubated in 6-well plates with various concentrations of H31, treated with 200 mg/mL RNase A, and stained with 5 mg/
mL PI. The stained cells were then analyzed with a FACS caliber instrument. (D) Annexin V and PI staining. To quantify the effects of H31 on 
apoptosis, annexin V-FITC and propidium iodide staining were used to analyze the percentage of apoptotic cells treated with H31. The data 
represent the mean±SD of three independent experiments. **P<0.01, ***P<0.001 by student t-test, compared to medium alone.
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µM of H31, while death of all eggs was noted with 100 µM of 
cisplatin. Next, we investigated the neurotoxicity of H31 using 
the zebrafish neuromast. As shown in Fig. 5B, doses of H31 that 
were increased up to 100 µM did not decrease the number of 
hair cells of the neuromast; by contrast, there was almost total 
loss of the hair cells of the neuromast with 100 µM cisplatin. 
Extraction of a pure single compound using the HPLC method
We have extracted several PCCs from the crude extract of H31 
using the HPLC method. Two PCCs demonstrated strong cyto-
toxicity among the cell lines: FaDu, KB AGC, HepG2, and HT-
29 by the MTT assay (data not shown). Therefore, additional 
HPLC studies were carried out on one PCC among them. The 
MTT assay of KB cells was performed using several substances 
that showed possible tumor suppression. As shown in Fig. 6, the 
PCC that showed the highest peak in the HPLC study showed 
strong cytotoxicity in the KB cells at a concentration of 10 µg/
mL. Therefore, this single compound appears to possess the anti-
tumor capabilities of H31.
DISCUSSION
Marine micro-organisms are increasingly used as a source for 
anti-cancer agents (17). Cytarabine, the extract of nucleosides 
from the Caribbean sponge and Cryptotheca crypta, are now 
routinely used for the treatment of patients with leukemia and 
lymphoma (17). Jeong et al. (18) reported that a compound 
from Bacillus vallismortis showed direct cytotoxic and apoptotic 
effects on colon cancer cells in a dose and time dependent man-
ner. In an attempt to identify a novel compound for cancer ther-
apy, the results of this study show that H31, from the Bacillus 
SW31, had cytotoxic and apoptotic properties in head and neck 
cancer cells. 
  One therapeutic approach to the control of cancer cells in-
volves the induction of apoptosis (19). Whether H31 could in-
duce apoptosis in head and neck cancer cells was studied, as a 
potential method of growth inhibition. The results of this study 
showed that H31 suppressed KB cells and SCC VII/SF cell 
growth in vitro and in vivo, respectively, and the mechanism in-
volved was mediated by up-regulation of p53 expression and 
activation of caspase-3. 
  Apoptosis is caused by the activation of cysteine protease, 
known as caspases, and the subsequent cleavage of certain cel-
lular substrates (20-22). Of the 14 currently known human cas-
pase family members, caspase-3 is the key factor associated with 
apoptosis; its active form is pivotal in the breakdown of cellular 
activity connected with DNA repair and regulation (23). The 
findings of this study showed that caspase-3 expression was up 
regulated when the cells were treated with H31, suggesting that 
the apoptotic-action of H31 was associated with caspase-3 in-
volvement. 
p-JNK
p-P53 (ser15) (M)
p-P53 (ser15) (C)
Cyto-c (M)
Cyto-c (C)
Procaspase3 (C)
Cleaved caspase3 (C)
β-actin
H31/24 hours
0  10  50  100       (μg/mL)
Fig. 3. Expression of apoptosis-associated proteins: KB cells were 
treated with H31 at the indicated concentrations. Serum-starved KB 
cells were treated with different concentrations of H31, and then 
Western blotting was performed with various antibodies, including 
p-JNK, p-p53, cytochrome C, procaspase 3, and cleaved cas-
pase-3. 
cells, we investigated several factors related to apoptotic path-
ways, including c-jun, p53, cytochrome C, and caspase-3. As 
shown in Fig. 3, the expression of phosphorylation of JNK and 
p53 was increased in a dose-dependent manner. Cytochrome C, 
which triggers the mitochondrial apoptotic pathway, was in-
creasingly released from mitochondria into the cytosol by H31. 
In addition, the expression of the active form of caspase-3 was 
increased at a concentration of 100 µg/mL.
H31 suppressed tumor growth in C3H/HeJ syngeneic mice 
To determine whether these results could be confirmed in vivo, 
we used the immunocompetent syngeneic mouse model (C3H/
HeJ mice, SCC VII/SF cell) and randomly divided the animals 
into two equal groups (control and treatment group, 0.2 mg/kg) 
after injection of SCC VII/SF cells. As shown in Fig. 4, the final 
volume (A), final weight (B), and time course volume change (C) 
of the SCC VII/SF tumors were significantly inhibited at 21 days 
after treatment with 0.2 mg H31 compared to the control group 
(D). For the TUNEL staining (Fig. 4E) and immunohistochemical 
study (Fig. 4F) of caspase-3, which was performed to observe 
the apoptosis induced by H31 in the tumor tissue removed from 
the C3H/HeJ syngeneic mice, the apoptotic index in the tumor 
tissue from the H31 injected mice was statistically higher than 
in the controls (P<0.01).
Evaluation of embryotoxicity and neurotoxicity of H31 in the 
zebrafish model
We used the zebrafish model for the toxicity assays of H31. 
First, we examined the embryotoxicity of H31. As shown in Fig. 
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HNSCC has been observed to result in a relative lack of apopto-
sis (25). Targeting p53 may be one approach to reduce the anti-
apoptotic features associated with HNSCC. Gene therapy using 
  The tumor suppressor protein, p53, is a central controlling 
modulator that receives specific signals, interprets complex in-
put, and determines regulatory output (24). The loss of p53 in 
Fig. 4. Effect of H31 on tumor growth and apoptosis in C3H/HeJ syngeneic mice. Six C3H/HeJ syngeneic mice with subcutaneous injections 
of 5×10
5 SCC VII cells were divided into two groups. Three were then given daily intraperitoneal injections of distilled water (control) and the 
other 3 mice were treated with 0.2 mg H31. After 22 days, the mice were sacrificed and tumors were removed. (A) Effect of H31 on tumor vol-
ume. (B) Effect of H31 on tumor weight. (C) Effect of H31 on tumor growth (time course). (D) Gross appearance. (E) Tissue TUNEL staining. (F) 
Immunohistochemistry for caspase-3. *P<0.01, **P<0.05.
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adenoviral transfer of p53 is being aggressively investigated as 
adjuvant therapy for head neck cancer cells (26). Therefore, H31 
may be an additional candidate for enhancing apoptosis of head 
and neck cancer cells. 
  Chemotherapy agents are often limited by drug toxicity (27). 
A new agent’s toxicity profile is a very important characteristic 
that should be defined during the drug discovery process. Re-
cently, the animal model using zebrafish (Danio rerio) has be-
come a useful technique to screen for cardiotoxicity, neurotoxic-
ity, hepatotoxicity, nephrotoxicity and genotoxicity of new can-
didate drugs (28-30). The results of this study showed that treat-
ment of zebrafish with 100 µM cisplatin resulted in nearly total 
loss of the neuromast by immunofluorescence, while 100 µM of 
H31 did not decrease the number of neuromast hair cells. In ad-
dition, normal zebrafish organogenesis occurred with 100 µM 
H31 treatment. 
Fig. 6. Extraction of a pure cytotoxic compound (PCC) of H31 using the HPLC method and results of the MTT assay: The PCC showed the 
highest peak (black arrow) and the HPLC showed strong cytotoxicity to KB cells in the concentration of 10 µg/mL. This single compound ap-
pears to possess the anti-tumor capabilities of H31. ***P<0.001.
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Fig. 5. Zebrafish assay for the evaluation of embryotoxicity and neurotoxicity of H31: (A) Embryotoxicity: wild type zebrafish were maintained at 
28.5°C on a 14 hours light/10 hours dark cycle, then fertilized eggs were exposed to the indicated concentrations of H31 or 100 µM cisplatin, 
and maintained in a incubator at 28.5°C for 1 hour. After H31 treatment, egg death, organogenesis, hatch rate, and any abnormal features 
were evaluated; (B) Neurotoxicity: The 4 dpf zebrafish were treated with cisplatin (50 µM, 100 µM) or increasing concentrations of H31 for 24 
hours and then were stained with YO-PRO1. White dots on the body of zebrafish indicate neuromasts.Lim YC et al.: Anticancer effect of H31 Metabolites from Marine Bacillus SW31    225
  In conclusion, the results of this study demonstrated that 
growth inhibition and apoptosis was achieved both in vitro and 
in vivo in head and neck cancer cells after exposure to H31, a 
metabolite from the marine Bacillus species. The zebrafish mod-
el did not reveal any significant toxicity effects even at consider-
able H31 dose concentrations. Although further characterization 
of the chemical structure and biological activities of HPLC puri-
fied PCC is necessary, our results suggest that H31 appears to 
be a safe candidate for apoptosis-inducing anti-cancer treatment 
of head and neck cancer. 
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